-
WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges
•
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued performance for the first half of 2024, with its financial report indicating a decline in revenues and net profits. Revenues for the period stood at RMB 17.241 billion (USD 2.38 billion), marking an 8.64% year-on-year…
-
Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand
•
Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second quarter of 2024, showing a 2% increase in group sales to €4.5 billion (USD 4.9 billion) on a year-over-year basis, excluding currency impacts. This positive performance was met with a significant stock price increase of…
-
Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment
•
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of 2024, with global sales increasing by 11% year-on-year to $12.2 billion, based on constant exchange rates. The growth was driven in part by the company’s ‘growth portfolio,’ which includes a dozen newer drugs that saw…
-
AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges
•
AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024, demonstrating a solid year-on-year (YOY) growth of 5.6% in constant currency terms, reaching $14.462 billion in revenue. The company’s long-standing blockbuster drug, Humira (adalimumab), continues to face biosimilar competition, resulting in a 28.9% YOY decline…
-
Roche’s H1’24 Financials Show 5% Growth, Eye Care and Cancer Therapies Drive Sales
•
Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO), the Swiss pharmaceutical and diagnostics giant, has reported its financial results for the first half of 2024, with group sales remaining stable in Swiss franc terms. However, on a constant exchange rate basis, sales increased by 5% year-on-year to CHF 29.85 billion (USD…
-
AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines
•
AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second quarter and the first half of 2024, demonstrating robust growth. For the six-month period, total revenues increased by 18% year-on-year (YOY) to $25.617 billion, with product sales also experiencing an 18% rise to $24.629 billion.…
-
Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions
•
Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results for the second quarter of 2024, demonstrating a robust year-on-year growth of 10.2% in global net sales, reaching €10.745 billion (USD 11.64 billion) in constant currency terms. This growth was driven by the company’s Pharma…
-
Novartis Delivers Strong Q2 2024 Results with 11% YoY Net Sales Increase
•
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has released its financial results for the second quarter of 2024, demonstrating sustained strong performance akin to the first quarter of this year. Net sales experienced a robust 11% year-on-year (YOY) increase in constant currency terms, reaching USD 12.5 billion for the quarter.…
-
J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure
•
Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged goods manufacturing company, has reportedly discontinued the development of its pipeline epilepsy therapy ADX71149, according to the company’s latest Q2 2024 financials report and information from FiercePharma.com. ADX71149, a positive allosteric modulator (PAM) of metabotropic…
-
Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales
•
Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its financial results for the second quarter of 2024, highlighting a 9.3% year-on-year (YOY) increase in sales, reaching USD 10.4 billion in constant currency terms. The Medical Devices segment was the top performer, marking a 12.1%…
-
Johnson & Johnson Reports Robust Q2 2024 Earnings, Bolstered by Pharma and Medtech Growth
•
Johnson & Johnson (NYSE: JNJ) has reported its financial results for the second quarter of 2024, with global sales reaching USD 22.4 billion, reflecting a strong operational growth of 6.6% year-on-year, excluding currency impacts. When adjusting for COVID-19 sales, this growth rises to 7.2%. The company’s innovative medicine segment contributed…
-
Jiangsu Hengrui Pharmaceuticals Faces FDA Setback with Warning Letter for Quality Control Issues
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a prominent player in China’s pharmaceutical industry, has received a warning letter from the US Food and Drug Administration (FDA), following a Form 483 issued earlier this year in June. The FDA’s notice highlights two principal deficiencies at Hengrui’s facility: the company’s quality control unit…
-
Abbisko Therapeutics Forecasts Profits and Revenue Boost in H1 2024 on Merck Deal
•
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has released a positive financial forecast for the first half of 2024. The company anticipates total revenues to amount to RMB 497 million (USD 68.34 million) over the six-month period, marking a significant uptick. Additionally, Abbisko expects to report its…
-
MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) and spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) unveil their financial forecasts for the first half of 2024, along with business updates. MedBot anticipates a significant year-on-year…
-
Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth
•
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024, showing a slight 0.6% year-on-year (YOY) decrease in group sales to EUR 13.8 billion (USD 14.9 billion), excluding portfolio and exchange rate effects. The pharmaceuticals business segment reported a 3.9% increase in sales, reaching EUR…
-
Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial
•
Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific antibody (BsAb) Mim8 has successfully met the primary endpoints in a late-stage trial for haemophilia A. The trial focused on the reduction of treated bleeding episodes, with once-weekly and once-monthly doses of Mim8 showing reductions…
-
Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization
•
US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter of 2024, with global net sales remaining flat year-on-year (YOY) at USD 3.7 billion in constant currency terms. The base business brands experienced a 2% YOY decline to USD 2.3 billion, attributed to unfavorable channel…
-
Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip
•
Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been released, showing a 1.5% year-on-year increase in global revenues at constant exchange rates (CER), reaching JPY 4.3 trillion (USD 27.4 billion). This growth was achieved despite a significant impact from the loss of exclusivity on…
-
Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength
•
Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024, announcing sales of USD 2.5 billion, marking a 6% year-on-year (YOY) increase in constant currency terms. This growth was driven by contributions from all regions. Generics sales experienced a modest 1% YOY increase to USD…
-
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
•
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in global sales for the first quarter of 2024, reaching DKK 65.3 billion (USD 9.4 billion) at constant exchange rates (CER). The growth was primarily attributed to strong performances in glucagon-like peptide-1 (GLP-1)-based drugs and obesity…
